Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec;38(6):1095-1097.
doi: 10.1007/s10557-024-07615-8. Epub 2024 Aug 8.

How Much Is Enough?

Yochai Birnbaum  1 , Lisa Kay McClendon  2 , Masafumi Kitakaze  3
Affiliations
Editorial

How Much Is Enough?

Yochai Birnbaum et al. Cardiovasc Drugs Ther. 2024 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics Approval: Not relevant for an editorial. Consent to Participate: Not relevant for an editorial. Consent for Publication: Not relevant for an editorial. Competing Interests: Yochai Birnbaum, MD. No relevant financial or non-financial interests to disclose. Lisa Kay McClendon, PhD. No relevant financial or non-financial interests to disclose. Masafumi Kitakaze, MD. PhD: M.K. reports personal fees from Daiichi-sankyo, personal fees from Viatris, grants and personal fees from Ono, grants from Novartis, grants and personal fees from Tanabe-mitubishi, grants from Takeda, grants and personal fees from Astra Zeneca, grants and personal fees from Boehringer-ingelheim, grants from Kowa, personal fees from Otsuka, and personal fees from Eli Lilly outside the submitted work.

References

    1. Jiang L, Xiong W, Yang Y, Qian J. Insight into cardioprotective effects and mechanisms of dexmedetomidine. Cardiovasc Drugs Ther. 2024. https://doi.org/10.1007/s10557-024-07579-9 . - DOI - PubMed
    1. Chen J, Jiang Z, Zhou X, et al. Dexmedetomidine preconditioning protects cardiomyocytes against hypoxia/reoxygenation-induced necroptosis by inhibiting HMGB1-mediated inflammation. Cardiovasc Drugs Ther. 2019;33(1):45–54. https://doi.org/10.1007/s10557-019-06857-1 . - DOI - PubMed
    1. Wang T, Li Z, Xia S, et al. Dexmedetomidine promotes cell proliferation and inhibits cell apoptosis by regulating LINC00982 and activating the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT) signaling in hypoxia/reoxygenation-induced H9c2 cells. Bioengineered. 2022;13(4):10159–67. https://doi.org/10.1080/21655979.2022.2060900 . - DOI - PubMed - PMC
    1. Wang Z, Yao M, Jiang L, et al. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3beta/Nrf2 axis. Biomed Pharmacother. 2022;154: 113572. https://doi.org/10.1016/j.biopha.2022.113572 . - DOI - PubMed
    1. Ma X, Xu J, Gao N, Tian J, Song T. Dexmedetomidine attenuates myocardial ischemia-reperfusion injury via inhibiting ferroptosis by the cAMP/PKA/CREB pathway. Mol Cell Probes. 2023;68: 101899. https://doi.org/10.1016/j.mcp.2023.101899 . - DOI - PubMed

Publication types

LinkOut - more resources